Global Antibiotic Resistance Market, By Drug Class, By Disease (cUTI, CDI, ABSSSI, HABP, CABP, cIAI, Others (BSI, etc.)), By Distribution Channel, By Geography .

Description

The global antibiotic resistance market was valued US$ 8.83 Bn in 2023 and is expected to reach US$ 13.37 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 8.83 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	5.30%	2030/2031 Value Projection:	US$ 13.37 Bn

Figure 1. Global Antibiotic Resistance Market Share (%), By Region, 2023

Global Antibiotic Resistance Market - IMG1

The global antibiotic resistance market has been witnessing significant growth in recent years. Antibiotics are medicines used to prevent and treat bacterial infections. They either kill bacteria or stop them from multiplying. Some of the most commonly used antibiotics include penicillin, amoxicillin, cephalosporins etc. However, over the past few decades, antibiotic resistance has been emerging as a major public health threat globally. When bacteria become antibiotic resistant, the medicines used to treat the infections they cause become ineffective. This leads to longer illness and increased death rates. The rising prevalence of bacterial strains that are resistant to various antibiotic classes is primarily attributable to misuse and overuse of antibiotics. Other factors that drive antibiotic resistance include the lack of development of new antibiotics, lack of sanitation and hygiene in many parts of the world, increased international travels, etc. If not addressed properly, antibiotic resistance could lead to serious health issues and affect patient outcomes.

Market Dynamics:

The global antibiotic resistance market growth is driven by various factors such as increasing prevalence of antibiotic-resistant bacterial infections, lack of new antibiotic development, misuse and overuse of existing antibiotics, limited infection control in many developing regions, etc. However, the development of alternative treatment options and stringent regulations regarding antibiotic usage could restrain the market growth. The market provides opportunities for companies focusing on the development of novel antibiotics with new mechanisms of action. Key players are also exploring alternative therapeutic approaches like phage therapy, vaccines, monoclonal antibodies etc. to counter antibiotic resistance. Partnerships between industry and academia hold promise to address this looming healthcare crisis.

Key Features of the Study:

This report provides an in-depth analysis of the global antibiotic resistance market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antibiotic resistance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceutials, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, NEMESIS BIOSCIENCE LTD.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antibiotic resistance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibiotic resistance market

Detailed Segmentation:

Global Antibiotic Resistance Market, By Drug Class
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Cephalosporins
- Others (Combination therapies, etc.)
Global Antibiotic Resistance Market, By Disease
- cUTI (Complicated Urinary Tract Infections)
- CDI (Clostridioides difficile Infection)
- ABSSSI (Acute bacterial skin and skin structure infections)
- HABP (Hospital-acquired bacterial pneumonia)
- CABP (Community-acquired pneumonia)
- cIAI (Complicated intra-abdominal infection)
- Others (BSI (Bloodstream infection), etc.)
Global Antibiotic Resistance Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Antibiotic Resistance Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Top Companies in the Global Antibiotic Resistance Market:
- Melinta Therapeutics
- Merck & Co., Inc.
- Allergan
- Pfizer Inc.
- Tetraphase Pharmaceutical, Inc.
- Theravance Biopharma
- WOCKHARDT
- Entasis Threapeutics
- Paratek Pharmaceutials, Inc.
- Seres Therapeutics
- Achaogen Inc.
- Basilea Pharmaceutical Ltd.
- Nabriva Threapeutics plc
- NEMESIS BIOSCIENCE LTD.

Product Code: CMI6668

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rising prevalence of infectious diseases
- Advancement in antibiotic resistance diagnosis
- Growing number of R&D activities
Key Highlights
Guidelines for the Temporary Staffing Agency & the Host Employer
Market Trends
PEST Analysis
Investments and Fundings
Mergers, Acquisitions, and Collaborations
Key Services Offered
Identification of Top Market Players
Nurse Staffing Dominance
Healthcare Spending by Country

4. Global Antibiotic Resistance Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Antibiotic Resistance Market, By Drug Class, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oxazolidinones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Lipoglycopeptides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Tetracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Cephalosporins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Others (Combination therapies, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global Antibiotic Resistance Market, By Disease, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
cUTI (Complicated Urinary Tract Infections)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
CDI (Clostridioides difficile Infection)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
ABSSSI (Acute bacterial skin and skin structure infections)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
HABP (Hospital-acquired bacterial pneumonia)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
CABP (Community-acquired pneumonia)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
cIAI (Complicated intra-abdominal infection)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Others (BSI (Bloodstream infection), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global Antibiotic Resistance Market, By Distribution Channel, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global Antibiotic Resistance Market, By Region, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020 - 2031
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profile
- Melinta Therapeutics
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Merck & Co., Inc.
- Allergan
- Pfizer Inc.
- Tetraphase Pharmaceutical, Inc.
- TeamHealth
- Theravance Biopharma
- WOCKHARDT
- Entasis Threapeutics
- Paratek Pharmaceutials, Inc.
- Seres Therapeutics
- Achaogen Inc.
- Basilea Pharmaceutical Ltd.
- Nabriva Threapeutics plc
- NEMESIS BIOSCIENCE LTD.
Analyst Views

10. Section

References
Research Methodology
About us